Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

(2020) Francesco Schettini et al.   CANCER TREATMENT REVIEWS

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

(2020) Fara Brasó-Maristany et al.   Nature Communications

138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses

(2020) G. Jerusalem et al.   ANNALS OF ONCOLOGY

A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.

(2020) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.

(2020) Dongmei Ji et al.   JOURNAL OF CLINICAL ONCOLOGY

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

(2020) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

(2020) Sara M Tolaney et al.   LANCET ONCOLOGY

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

(2020) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

(2019) Sherene Loi et al.   LANCET ONCOLOGY

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

(2019) T Bachelot et al.   ANNALS OF ONCOLOGY

Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.

(2019) Zefei Jiang et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

(2019) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade

(2019) Aleix Prat et al.   JNCI-Journal of the National Cancer Institute

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

(2019) Edith A. Perez et al.   BMC CANCER

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

(2019) Liese Barbier et al.   BRITISH JOURNAL OF CANCER

305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

(2019) L A Emens et al.   ANNALS OF ONCOLOGY

LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

(2019) S M Tolaney et al.   ANNALS OF ONCOLOGY

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

(2019) Fei Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

(2019) Bo Wang et al.   Scientific Reports

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

(2018) Sarika Jain et al.   BREAST CANCER RESEARCH AND TREATMENT

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

(2018) Noam Pondé et al.   CANCER TREATMENT REVIEWS

A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial

(2018) Yeon Hee Park et al.   INTERNATIONAL JOURNAL OF CANCER

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer

(2018) Virginia F. Borges et al.   JAMA Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

(2018) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

(2017) Mathilde Guerin et al.   EUROPEAN JOURNAL OF CANCER

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

(2017) Antonio Llombart-Cussac et al.   LANCET ONCOLOGY

Intrinsic molecular subtypes of HER2+ breast cancer

(2017) Aleix Prat et al.   Oncotarget

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

(2016) J. Baselga et al.   CLINICAL CANCER RESEARCH

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

(2016) Anthony Ferrari et al.   Nature Communications

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2015) Xavier Pivot et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

(2014) Aleix Prat et al.   JNCI-Journal of the National Cancer Institute

A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer

(2012) Fausto Petrelli et al.   Clinical Breast Cancer

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

(2012) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

(2011) T Waddell et al.   BRITISH JOURNAL OF CANCER

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

(2011) A. M. Brufsky et al.   CLINICAL CANCER RESEARCH

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?

(2011) Y.-N. Wong et al.   ONCOLOGIST

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer

(2009) Denise A. Yardley et al.   Clinical Breast Cancer

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

(2009) Christos Christodoulou et al.   ONCOLOGY

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT